NS1209

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
01220022016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical Research The selective AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, NS1209 (also… (More)
Is this relevant?
Review
2016
Review
2016
Currently information is available for 20 potential anti-seizure drugs in clinical development. They include candidates with… (More)
Is this relevant?
2013
2013
Refractory status epilepticus (RSE) is a life-threatening condition that requires immediate and aggressive treatment… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
Epileptogenesis, i.e., the process leading to epilepsy, is a presumed consequence of brain insults including head trauma, stroke… (More)
Is this relevant?
2009
2009
BACKGROUND Chronic neuropathic pain is inadequately treated using current therapies, with less than half of patients achieving… (More)
  • figure 2
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2007
2007
The current first line treatment of status epilepticus (SE) is based on the use of compounds that enhance GABAergic transmission… (More)
Is this relevant?
2004
2004
The effects of systemic administration of the novel AMPA/GluR5 selective receptor antagonist NS1209 in animal models of… (More)
Is this relevant?
2004
2004
Previous studies have shown that repeated injections of acidic saline, given into the lateral gastrocnemius muscle of rats… (More)
Is this relevant?
2002
2002
The spared nerve injury (SNI) model involves a lesion of two of the three terminal branches of the sciatic nerve (tibial and… (More)
Is this relevant?
Review
2002
Review
2002
The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in Sitges, Barcelona from the 10th to 14th… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?